Brochure
27 Oct 2021
APPLIVER FIBROSIS
PDF 713 kB
APPLIVER® is the new product obtained by the ABR innovative biotechnological platform NATRISE®.
Our research studies confirm the beneficial effect on health of APPLIVER® in metabolic disorder as NAFLD.
This makes APPLIVER® the perfect ingredient for dietary supplements and functional foods.
Content provided by our supplier
ABResearch srl
-
Country/Region:Italy
-
On CPHI since:2020
-
Certificates:3
-
Employees:25 - 49
Company types
Other Content from ABResearch srl (1)
-
News Anti-fibrotic properties of APPLIVER on in vitro models of non-alcoholic steatohepatitis
In collaboration with the research groups of Fondazione Italiana Fegato Onlus (FIF) APPLIVER™ was tested in in vitro model of non-alcoholic fatty liver disease (NAFLD), characterized to develop fibrosis.